New long-term clinical data for Johnson & Johnson’s TREMFYA (guselkumab) in ulcerative colitis has been released, showing notably consistent results. For investors, the durability of a therapy over multiple years is a critical consideration in the chronic disease treatment market, often outweighing the importance of short-term effect alone.
Study Details and Key Outcomes
The findings, presented on February 21, 2026, originate from the QUASAR Long-Term Extension study. The research focused on whether the drug’s efficacy in patients with moderate to severe active ulcerative colitis is maintained over an extended period.
After 140 weeks of treatment, 80.8% of patients receiving TREMFYA were in clinical remission. This highlights the therapy’s potential to provide sustained disease control rather than a temporary response.
A particularly compelling data point concerns persistence: among patients who had already achieved clinical remission by week 44, a substantial 87.5% maintained that status through to week 140. This consistency is frequently the pivotal challenge for long-term treatment regimens.
Assessing Deeper Tissue-Level Improvement
Beyond tracking symptomatic remission, Johnson & Johnson reported outcomes based on endoscopic and histological parameters. These measure the visual and cellular-level condition of the intestinal lining.
Should investors sell immediately? Or is it worth buying Johnson & Johnson?
At the 140-week mark, 78.6% of patients achieved histo-endoscopic mucosal improvement (HEMI). This composite endpoint, which combines visible improvement with tissue-level assessment, is considered a more rigorous measure than symptom scores alone.
The company also noted that no new safety signals were identified during this extended study period, an important factor for comprehensive treatment evaluation.
Market Context and Insider Activity
Separate from the clinical data, a regulatory filing this week showed that Executive Vice President Vanessa Broadhurst sold shares of the company on February 17.
In Friday’s trading session, Johnson & Johnson shares closed slightly lower at €205.80, representing a decline of 1.86%. Despite this daily move, the stock continues to trade near its 52-week high, a level it reached earlier in the week. This proximity suggests the market’s overall assessment of recent company developments has not shifted negatively.
Ad
Johnson & Johnson Stock: Buy or Sell?! New Johnson & Johnson Analysis from February 22 delivers the answer:
The latest Johnson & Johnson figures speak for themselves: Urgent action needed for Johnson & Johnson investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 22.
Johnson & Johnson: Buy or sell? Read more here...
